Nov 7, 2016 | Publication
Abstract – The magnitude of the 2013-2016 Ebola virus disease (EVD) epidemic enabled an unprecedented number of viral mutations to occur over successive human-to-human transmission events, increasing the probability that adaptation to the human host occurred... 
Oct 1, 2016 | Publication
Abstract – Lassa fever is a significant health threat to West African human populations with hundreds of thousands of annual cases. There are no approved medical countermeasures currently available. Compassionate use of the antiviral drug ribavirin or... 
Aug 22, 2016 | Press release
Opens Advanced Product Development Center in Colorado GERMANTOWN, MD AND DENVER – August 22, 2016 – Zalgen Labs, a biotechnology and diagnostics company focused on high-impact, neglected infectious diseases, announced that it has received via transfer the viral... 
Aug 11, 2016 | Publication
Background – The 2013-2016 West African Ebola virus disease (EVD) epidemic is the largest recorded. Triage on the basis of clinical signs had limited success, and the time to diagnosis by quantitative reverse transcription-polymerase chain reaction (qRT-PCR)... 
Jul 12, 2016 | Publication
In two separate articles published in The Journal of Infectious Diseases, VHFC researchers from Nigeria and Sierra Leone provide key insights into the Ebola outbreak response that took place during the 2013-2016 Ebola epidemic. In An Outbreak of Ebola in the Lassa... 
Jun 30, 2016 | Publication
The recent outbreaks of Ebola and Zika virus have highlighted how health system failures in seemingly geographically remote areas can result in disease vulnerabilities across the globe. In the absence of a stable health care infrastructure or adherence to immunization...May 18, 2016 | Publication
Lassa fever is a severe multisystem disease that often has haemorrhagic manifestations. The epitopes of the Lassa virus (LASV) surface glycoproteins recognized by naturally infected human hosts have not been identified or characterized. Here we have cloned 113 human...
